The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

AACR convenes conference on health disparities

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The American Association for Cancer Research, in association with the AACR Minorities in Cancer Research Council, will host a virtual meeting on cancer health disparities Oct. 2-4, 2020.

The Virtual 13th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved aims to advance the understanding of, and ultimately help to eliminate, the disparities that represent a major public health problem in the United States.

The meeting program will include discussion of diversity and inclusion in clinical trials; disparities in cancer risk and treatment among the LGBTQ population; cancer prevention and screening in adolescents and young adults; precision oncology in diverse populations; financial toxicity for cancer patients; the impact COVID-19 has had on patients with cancer; diversifying the cancer research workforce; and more.

The full program is available here. The meeting will build on the themes and data reported in the inaugural AACR Cancer Disparities Progress Report, published Sept. 16, 2020. Read the full report.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account